



**TRADING UPDATE 1ST QUARTER 2007**


**Strong growth in both divisions**

Nazareth, Belgium 19 April 2007 — The consolidated turnover of the Omega Pharma group amounted to 275.9 million euro in the First Quarter of 2007. This is 12.3 per cent above the figure for the same period last year. The growth of the quarter is evenly spread over Consumer Health (OTC) and Professional Health (Arseus). In Consumer Health, Omega Pharma France, Omega Pharma Southern Europe and Bittner Pharma demonstrated good sales figures, while in Professional Health, Arseus Medical has now also reached the turning point. This strengthens confidence for the entire year.

The turnover per reporting segment is as follows:

Non-audited management figures in EUR million	Q1/2007	Q1/2006	% evolution 2007/2006
Omega Pharma Belgium	54.2	53.9	+1%
Omega Pharma France	45.6	44.0	+4%
Omega Pharma Northern Europe	23.5	23.2	+1%
Omega Pharma Southern Europe	44.8	37.3	+20%
Omega Pharma Rest of the World (ROW)	36.6	21.7	+69%
<b>Consumer Health (OTC)</b>	<b>204.8</b>	<b>180.1</b>	<b>+14%</b>
Fagron Group	24.2	23.1	+5%
Corilus	6.1	6.4	-5%
Arseus Dental	28.8	24.5	+18%
Arseus Medical	12.0	11.5	+4%
<b>Professional Health (Arseus)</b>	<b>71.1</b>	<b>65.5</b>	<b>+9%</b>
<b>Total Omega Pharma</b>	<b>275.9</b>	<b>245.6</b>	<b>+12%</b>

**Contribution to the consolidated group turnover in the First Quarter 2007**



- Omega Pharma Belgium
- Omega Pharma France
- Omega Pharma Northern Europe
- Omega Pharma Southern Europe
- Omega Pharma 'Rest of the World'
- Fagron Group
- Corilus
- Arseus Dental
- Arseus Medical

**Omega (OTC): 74%**

**Arseus (B2B): 26%**

## OMEGA CONSUMER HEALTH (OTC)

The quarterly turnover of the Consumer Health organization is almost 14 per cent higher than in the comparable period last year. The internal growth is approximately 5 per cent and is above the growth of the total OTC market, which is estimated at 3 per cent. As indicated at the analyst meeting of 1 March 2007, the First Quarter sales growth of Omega Pharma Belgium and Omega Pharma France is below the full-year, because of the strong results in the comparable period last year. The sales of all Core Categories have evolved as scheduled. In this context, the 14 per cent sales growth of Predictor (home diagnostics) is notable, particularly because the widened product range has currently only been introduced in a limited number of countries.

- **Omega Pharma Belgium.** A slight growth of turnover from generic medicines, decreasing distributions, and strong sales of our own in-house brands together led to a 1 per cent growth in the turnover. The distribution of the generic medicines of Eurogenerics (Stada) grew at a lower pace, but in parallel with the evolution of the total market for generics in Belgium. As for the own brands, the two Star Brands, Wartner (wart treatment) and Predictor (home diagnostics), have in particular generated strong sales growth.
- **Omega Pharma France.** For the third consecutive quarter (since the restructuring of the sales teams in the second quarter 2006), the French organization has registered a growth in turnover, which amounts to 4 per cent for this quarter. The Core Categories dermatotherapeutics (Cryopharma/Wartner), slimming products (XL-S), home diagnostics (Predictor), and dermocosmetics (including Eau Précieuse) in particular demonstrate a nice increase in turnover. This also illustrates that the renewed organization has improved its capability of implementing the brand strategy of the group.
- **Omega Pharma Northern Europe.** The structural health of this regional organization remains unchanged at its high level. Since the brand portfolio in this region is proportionally geared more to winter ailments in the first quarter, the mild winter season has slowed the growth in turnover. This factor is also valid for the entire OTC market in this region.
- **Omega Pharma Southern Europe.** The same climatologic factor turned out to have a positive impact on the turnover in Southern Europe. The turnover of two Core Categories, slimming agents and anti-insect products in particular, is significantly higher than in the same period last year. In addition, the quarterly turnover of Predictor is at a high level.
- **Omega Pharma Rest of the World (ROW).** The 69 per cent growth in turnover reflects a strong turnover of Bittner Pharma (rounded at 14 million euro), which was included into the consolidation circle for the first time in the first quarter. This figure corresponds to the internal forecast for Bittner Pharma in the first quarter. In the Russian Federation, sales growth did not evolve optimally because of the already mentioned climatologic circumstances. The turnover in the other countries in Central and Eastern Europe was above the internal estimates. The integration of Bittner Pharma is evolving smoothly, thus enabling staff to spend more time and attention on the preparation of cross-selling opportunities. In this context, the Wartner wart treatment product is still expected to be launched onto the Russian market this year.

## ARSEUS PROFESSIONAL HEALTH (B2B)

The quarterly turnover of the Professional Health organization is 9 per cent higher than in the same period last year. This firm increase illustrates that the restructuring and reorientation exercises of 2006 have started to bear fruit. Thanks to the efforts, the know-how and the motivation of the entire Arseus team, this organization has not missed the start in this reference year. Anticipating the planned split-off and IPO scheduled for 2008, Arseus intends to demonstrate the strength of its renewed business model during each quarter of 2006.

- **Fagron Group.** With a 5 per cent increase in turnover, this organization is again performing on its traditional high level, and intends to continue this in a consistent way. The development of the Fagron brand into *the* European reference for in-pharmacy preparations is making further progress. Today, Fagron has already a direct presence in The Netherlands, Belgium, Germany and Spain, but from these countries the organization is also exploring operations in France and Portugal. Moreover, Fagron is currently analyzing to enter other European markets.
- **Corilus** (formerly known as OmegaSoft) is also beginning to see the results of the renewed business model. The decrease in turnover of the past quarters has been significantly reduced in the First Quarter 2007. Corilus is also better equipped to compensate for the general price erosion of computer hardware. In addition, the development of the new 'Vista-ready' software package for pharmacies — called Greenock — is entering the final test phase, in preparation of market introduction in the beginning of 2008. In addition, Corilus is generating a growing portion of its turnover with maintenance contracts and repeat purchases. This is a solid basis from which Corilus can start to grow again in the future.
- **Arseus Dental** has continued the sales growth that it already demonstrated in past quarters. This performance illustrates the potential of the 'buy and build' strategy, which is valid throughout the entire Arseus organization. In 2006, Arseus Dental has mainly strengthened its organizational platform, e.g. in France. Moreover, Arseus Dental has signed an exclusive distribution agreement for the German market with A-dec, the worldwide number one manufacturer of dental equipment. As a result, Arseus Dental now has exclusive distribution rights for A-dec in Belgium, The Netherlands, France, and Germany.
- **Arseus Medical** has demonstrated a remarkable performance in the First Quarter of 2007 by turning the decrease of turnover of the previous quarters back into growth (+4%). The decrease of turnover resulting from the termination of unprofitable distribution contracts could not yet be compensated by the turnover from new, more interesting distributions. In the First Quarter of 2007, this turning point has been reached. Moreover, the back office functions of Arseus Medical are almost fully centralized on a national level, enabling the organization now to further strengthen its commercial capabilities.

## PROGNOSES <sup>(1)</sup>

Omega Pharma confirms its prognosis for the 2007 group turnover of between 1,130 and 1,150 million euro. With the restructuring and refinement of the strategy introduced in 2006, the group also expects a further improvement in the profitability ratios at group level.

Thanks to the structural measures implemented in 2006, and to the access that the company has as of 2007 to the attractive OTC markets in Central and Eastern Europe, the Consumer Health division projects the 2007 turnover at between 830 and 850 million euro.

Arseus, the Professional Health division of the group, forecasts a sales growth of at least 6 per cent for 2007, with a target surpassing 300 million euro.

---

<sup>(1)</sup> Disclaimer: This press release contains forward-looking information which is based on current internal estimates and expectations as well as market expectations. Forward-looking statements contain inherent risks and apply exclusively on the date they are made. The actual results may differ substantially from those included in the forward-looking statements.

**For more information, please contact:**

[Chris.Vanraemdonck@omega-pharma.be](mailto:Chris.Vanraemdonck@omega-pharma.be)

Tel. 0032/9/381.03.31

Mobile 0032/499/58.55.31

**Financial calendar**

Monday 4 June 2007(7:00 PM CET) Annual General Shareholders Meeting

Thursday 19 July 2007 Trading update 2nd Quarter 2007

Wednesday 29 August 2007 Results 1<sup>st</sup> Half 2007

Thursday 18 October 2007 Trading update 3rd Quarter 2007

Thursday 17 January 2008 Trading update 4th Quarter 2007